| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | Pixel structure and display system utilizing the same | US13477674 | 2012-05-22 | US08810559B2 | 2014-08-19 | Du-Zen Peng; Tse-Yuan Chen; Chih-Chiang Tseng; Shou-Cheng Wang; Tsung-Yi Su |
| A pixel structure including a first switching transistor, a setting unit, a capacitor, a driving transistor, a second switching transistor and a luminous element is disclosed. The capacitor is coupled between a first and a second node. The first switching transistor transmits a data signal to the first node according to a scan signal. The driving transistor includes a threshold voltage and a gate coupled to the second node. The second switching transistor includes a gate receiving an emitting signal. The luminous element is coupled to the driving transistor and the second switching transistor in series between a first operation voltage and a second operation voltage. The setting unit controls the voltage levels of the first and the second nodes to compensate the threshold voltage of the driving transistor. | ||||||
| 22 | Pixel unit and display device utilizing the same | US12885519 | 2010-09-19 | US08441599B2 | 2013-05-14 | Chen-Pang Kung; Cheng-Chung Lee; Yu-Yang Chang; Chung-I Lee |
| A pixel unit including a first sub-pixel is disclosed. The first sub-pixel includes a first display medium, a second display medium, a first driving device, and a second driving device. The first driving device drives the first display medium. The second driving device drives the second display medium. | ||||||
| 23 | Zirconia ceramics and infrared ray radiation elements utilizing the same | US3585390D | 1969-02-05 | US3585390A | 1971-06-15 | ISHIKAWA TADASHI |
| Black zirconia ceramics are prepared by firing a mixture containing more than 45 percent, by weight, of a Zr02.Si02 component, up to 25 percent, by weight of a mineralizer consisting of manganese oxide, at least one of oxides of iron, cobalt, nickel or chromium, and the balance of clay. The fired black zirconia ceramics emit a large quantity of infrared rays of long wavelength when heated to about 500* C., and are suitable to effect, heating, baking, cooking, drying, etc.
|
||||||
| 24 | Thermoelectric materials and elements utilizing them | US46580654 | 1954-11-01 | US2762857A | 1956-09-11 | LINDENBLAD NILS E |
| 25 | Pixel unit and display device utilizing the same | US11563718 | 2006-11-28 | US07659956B2 | 2010-02-09 | Yeong-Feng Wang; Chun-Hao Tung; Liang-Bin Yu |
| A pixel unit comprising a first metal layer and a second metal layer. The first metal layer comprises a gate electrode and a first electrode. The second metal layer comprises a drain electrode, a source electrode, and a second electrode. The drain electrode overlaps the gate electrode in a first overlapping region. The source electrode overlaps the gate electrode in a second overlapping region. The second electrode overlaps the first electrode in a third overlapping region. The size of the first electrode approximates that of the second electrode. The first electrode and the second electrode are staggered. | ||||||
| 26 | CELLULOSE FIBERS AND THEIR USE IN REDUCING VOC EMISSIONS | EP02731664.5 | 2002-05-04 | EP1385911A1 | 2004-02-04 | TOCK, Richard W.; A'HERN, Daniel W. |
| Cellulosic materials are used for reducing VOC emission during polymer processing. The cellulosic material is prepared from any of several agricultural by-products including cotton burrs, cotton stalks, corn stalks, flax, hemp, wood flour, and many other plant materials. In one aspect, the present involves the use of the cellulosic material to absorb VOCs during the curing of thermoset resins when VOCs are released during the polymerization process. The cellulosic material is added directly to the wet resin surface during cure or to the liquid resin prior to processing. In the latter case, cotton burrs and other cellulosic materials having a lignin content of from about 5 to about 10% allow the cellulosic material to be incorporated into the resin with beneficial results. The cellulosic material is also used in filter elements or adsorption beds to reduce VOC emission during polymerization of both thermoplastic and thermoset resins. | ||||||
| 27 | Rifamycin hydrazones, pharmaceutical compositions containing them and their use | US644886 | 1984-08-27 | US4551450A | 1985-11-05 | Peter Traxler |
| Novel hydrazones derived from 3-formylrifamycin S or SV as the aldehydo component and a bi- or tri-cyclic N-aminopiperazine as the hydrazino component and having the formula ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6, independently of one another, each represents a hydrogen atom or C.sub.1-4 -alkyl,m and n, independently of one another, each represents an integer from 0 to 5,X represents C.sub.1-5 -alkylidene, benzylidene or C.sub.1-4 -alkoxymethylene,Y represents C.sub.1-5 -alkylidene, C.sub.1-4 -alkoxymethylene, oxy, thio or optionally substituted imino of the formula --N(R)-- wherein R represents hydrogen, C.sub.1-4 -alkyl, C.sub.3-5 -alkenyl, C.sub.3-12 -cycloalkyl or phenyl, orX and Y together represent 1,2-cycloalkylene or o-phenylene each of which can be substituted by from one to three C.sub.1-4 -alkyl radicals, andRif represents a radical of rifamycin S or SV that is bonded in the 3-position by the free valency,are distinguished by a high and long-lasting antituberculotic activity. They are manufactured in conventional manner, for example by condensation of their components. | ||||||
| 28 | Analogs of calicheamicin gamma1I, method of making and using the same | US915071 | 1992-07-16 | US5264586A | 1993-11-23 | Kyriacos C. Nicolaou; Adrian L. Smith; Chan-Kou Hwang; Emmanuel Pitsinos |
| Chimeric analogs of calicheamicin that include an analog of calicheamicinone linked to an ester or glycoside, (-)-calicheamicinone and its analogs are disclosed. | ||||||
| 29 | Rifamycins derivatives and preparation and pharmaceutical compositions thereof | EP84102651.1 | 1984-03-11 | EP0119571A1 | 1984-09-26 | Bruzzese, Tiberio; Dell'Acqua, Ernani; van den Heuvel, Holger Hans |
The invention relates to new rifamycins derivatives endowed with antibiotic activity and process for their preparation. The new rifamycins derivatives have the formula:
|
||||||
| 30 | Substituted benzoxazinorifamycin derivative and antibacterial agent containing the same | US324499 | 1989-03-16 | US4965261A | 1990-10-23 | Fumihiko Kanoo; Takehiko Yamane; Hideo Kondo; Takuji Hashizume; Katsuji Yamashita; Kazunori Hosoe; Fumiyuki Kuze; Kiyoshi Watanabe |
| A rifamycin derivative having the formula (I): ##STR1## wherein R.sup.1 is hydrogen atom, methyl group or ethyl group, R.sup.2 is an alkyl group having 1 to 4 carbon atoms, and A is a group having the formula: ##STR2## in which n is an integer of 3 to 5, or group having the formula: ##STR3## in which R.sup.3 is a alkyl group having 1 to 5 carbon atoms; or a salt thereof. The rifamycin derivative (I) exhibits a strong antibacterial activity against Gram-positive bacteria and acid-fast bacteria, and also exhibits a strong antibacterial activity against tubercle bacilli. | ||||||
| 31 | Ferritic steel sheet excellent at strain rate sensitivity of the flow stress, and automobile utilizing it | US09601272 | 2000-07-28 | US06432228B1 | 2002-08-13 | Akihiro Uenishi; Yukihisa Kuriyama |
| The present invention provides a ferritic steel sheet, the quasi-static strength of which is enhanced and further the dynamic strength of which is not lowered. There is provided a ferritic steel sheet excellent at strain rate sensitivity characterized in that: Co and/or Cr are contained at pot less than 0.01 mass % and not more than 4.0 mass % in total in the state of solid solution in the ferrite phase. | ||||||
| 32 | Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same | US826398 | 1986-02-05 | US4690919A | 1987-09-01 | Takehiko Yamane; Takuji Hashizume; Katsuji Yamashita; Kiyoshi Watanabe |
| A novel rifamycin derivative having the general formula (I): ##STR1## or salts thereof, a process for preparing the same and antibacterial agents containing the same as an effective component.The rifamycin derivative of the present invention having the general formula (I) shows a strong antibacterial activity against the Gram-positive bacteria and the acid-fast bacteria. | ||||||
| 33 | Imidazo-Rifamycine, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Präparate sowie ihre Verwendung | EP81810387.1 | 1981-09-21 | EP0049683A2 | 1982-04-14 | Kump, Wilhelm, Dr.; Traxler, Peter, Dr.; Scartazzini, Riccardo, Dr. |
N,N,Disubstituierte Derivate von 4-Aminoimidazolo-[4,5-c]rifamycin SV oder S der Formel
|
||||||
| 34 | Composition having a beneficial effect on the cardiovascular system, comprising monacolin K, lycopene and vitamin D3 | EP13173297.6 | 2013-06-21 | EP2815654A1 | 2014-12-24 | Eijgelaar, Wouter-Jan; Schoevers, Peter Alexander; Viëtor, Hendrik Engelbertus |
The present invention is in the field of medical treatment and relates to a formulation for oral administration, such as for instance in the form of tablets or of a powder, which is able to exert a beneficial effect on the cardiovascular system. More in particular, the invention provides a composition for oral administration having a beneficial effect on the cardiovascular system, comprising as active ingredients a mixture of monacolin K, lycopene and vitamin D3. |
||||||
| 35 | COMPOSITION FOR LONG-ACTING PEPTIDE ANALOGS | EP08797150.3 | 2008-08-04 | EP2185170A1 | 2010-05-19 | CASTILLO, Gerardo, M.; BOLITIN, Elijah, M.; CHAN, Elaine, K. |
| The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peρtide, wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing 1) an alkyl group having 6 to 36 carbon units, 2) a nitrilotriacetic acid group, 3) an imidodiacetic acid group, or 4) a moiety of formula (ZyHisw)p, wherein Z is any amino acid residue other than histidine, His is histidine, y is an integer from 0-6; w is an integer from 1-6; and p is an integer from 1-6; wherein if A has alkyl group with 6 to 36 carbon units x is greater than 0; and Cm is a cleavable moiety consisting of glycine or alanine or lysine or arginine or N-Arginine or N-lysine, wherein x is an integer between 0-6 and N may be any amino acid or none. The peptide analogs are complexed with polymeric carrier to provide enhanced half-life. | ||||||
| 36 | NEW SALTS OF PERINDOPRIL WITH BENZATHINE, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | EP10779347.3 | 2010-09-17 | EP2480231B1 | 2017-05-10 | Rucman, Rudolf; Zupet, Pavel |
| 37 | NEW BENZATHINE SALTS OF ACE INHIBITORS, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | EP10779347.3 | 2010-09-17 | EP2480231A2 | 2012-08-01 | Rucman, Rudolf; Zupet, Pavel |
| The present invention describes new salts of ACE inhibitors with N5N'-dibenzylethylenediamine (abbr.: benzathine salts), a process for their preparation in crystal and amorphous forms by the reaction of two moles of ACE inhibitors with one mole of N,N'-dibenzylethylenediamine, a process for the preparation of pharmaceutical formulations containing these salts and their use for the treatment of cardiovascular diseases. | ||||||
| 38 | (R/S) RIFAMYCIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | EP05791212.3 | 2005-07-21 | EP1768987B1 | 2009-04-01 | DING, Charles, Z.; MA, Zhenkun; LI, Jing; HARRAN, Susan; HE, Yong; MINOR, Keith, P.; KIM, In, Ho; LONGGOOD, Jamie, Carol; JIN, Yafei; COMBRINK, Keith, D. |
| Rifamycin derivatives having the following structure of general formula (I) (both hydroquinone and corresponding quinone (C1-C4) forms): or its salts, hydrates or prodrugs thereof; wherein a preferred R1 comprises hydrogen or acetyl and a prefered R2 comprises hydrogen, methyl or other lower alkyls; wherein asterik (*) denotes the carbon bearing the chiral center, wherein absolute configuration is assigned as R or S. Methods of preparation of the aforementioned rifamycin derivatives are also described. The compounds exhibit antimicrobial activities, including activities against drug-resistant microorganisms. | ||||||
| 39 | COMPOSITION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A DIURETIC AND ITS USE FOR THE TREATMENT OF HYPERTENSION | EP01982846.6 | 2001-11-19 | EP1336407B1 | 2006-05-03 | SADA, Toshio SANKYO COMPANY, LIMITED; MIZUNO, Makoto SANKYO COMPANY, LIMITED |
| [Constitution] Medicinal compositions comprising an angiotensin II receptor antagonist selected from among compounds having the following general formula (I) pharmacologically acceptable salts thereof, pharmacologically acceptable esters thereof and pharmacologically acceptable salts of the esters, and one or more diuretics. [Effects] Because of having an excellent hypotensive effect and little toxicity, these medicinal compositions are useful as preventives or remedies for hypertension or heart diseases. | ||||||
| 40 | Novel 4-desoxy-thiazolo (5,4-c) rifamycin derivatives and a process for preparing them | EP79100270.2 | 1979-01-30 | EP0005140A2 | 1979-11-14 | Cricchio, Renato; Berti, Marisa |
Novel 4-desoxy-thiazolo[5,4-c]rifamycin derivatives of formula I
The novel compounds have an antibacterial utility. |
||||||
QQ群二维码
意见反馈
意见反馈